Minot Light Capital Partners released its Q3 2025 investor letter, reporting a net return of 7.6% for limited partners, underperforming benchmarks like the micro-cap benchmark’s 17.1% return. The fund’s top five holdings for 2025 can be found in the letter. Lucid Diagnostics Inc. (NASDAQ:LUCD) was highlighted for its 0.92% one-month return and 43.92% gain over 52 weeks, closing at $1.10 per share on December 23, 2025, with a market cap of $144.209 million.

According to Minot Light Capital Partners’ Q3 2025 investor letter, Lucid Diagnostics Inc. (NASDAQ:LUCD) faced challenges despite marketing an FDA-approved DNA test for early esophageal precancer detection known as EsoGuard. The company sees a multi-billion dollar market opportunity for EsoGuard due to its unique capabilities, strong clinical data, and patient demand. However, reimbursement issues hinder adoption.

In Q3 2025, 11 hedge fund portfolios held Lucid Diagnostics Inc. (NASDAQ:LUCD), up from 8 in the previous quarter. The company reported $1.2 million in revenue, reflecting a 4% sequential increase and a 3% year-over-year increase. While Lucid Diagnostics Inc. (NASDAQ:LUCD) shows investment potential, Minot Light Capital Partners believes certain AI stocks offer better upside potential with less risk.

For more investor letters from hedge funds and leading investors, visit the hedge fund investor letters Q3 2025 page. Explore the best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that could double your money. This article is originally published on Insider Monkey.

Read more at Yahoo Finance: Here’s Why Lucid Diagnostics (LUCD) Declined in Q3